• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

9,11-断-胆固醇衍生物作为新型法尼醇X受体拮抗剂的发现

Discovery of 9,11-Seco-Cholesterol Derivatives as Novel FXR Antagonists.

作者信息

Zhou Jia-Xu, Li Cui-Na, Liu Ya-Meng, Lin Su-Qin, Wang Ying, Xie Cen, Nan Fa-Jun

机构信息

University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, People's Republic of China.

State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, People's Republic of China.

出版信息

ACS Omega. 2022 May 12;7(20):17401-17405. doi: 10.1021/acsomega.2c01567. eCollection 2022 May 24.

DOI:10.1021/acsomega.2c01567
PMID:35647433
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9134407/
Abstract

The farnesoid X receptor (FXR) plays an important role in the regulation of bile acid, lipid, and glucose homeostasis. Recent findings have shown that the inhibition of FXR is beneficial to improvement of related metabolic diseases and cholestasis. In the present work, 9,11-seco-cholesterol derivatives were designed and synthesized by cleaving the C ring of cholesterol and were identified as novel structures of FXR antagonists. Compound displayed the best FXR antagonistic activity at the cellular level (IC = 4.6 μM) and decreased the expression of the target genes of FXR .

摘要

法尼醇X受体(FXR)在胆汁酸、脂质和葡萄糖稳态的调节中发挥着重要作用。最近的研究结果表明,抑制FXR有助于改善相关代谢疾病和胆汁淤积。在本研究中,通过切割胆固醇的C环设计并合成了9,11-开环胆固醇衍生物,并将其鉴定为FXR拮抗剂的新结构。化合物在细胞水平上表现出最佳的FXR拮抗活性(IC = 4.6 μM),并降低了FXR靶基因的表达。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0587/9134407/9430465b613a/ao2c01567_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0587/9134407/405ff8fdb06d/ao2c01567_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0587/9134407/f6a839ff270e/ao2c01567_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0587/9134407/3d1afed1a949/ao2c01567_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0587/9134407/9430465b613a/ao2c01567_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0587/9134407/405ff8fdb06d/ao2c01567_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0587/9134407/f6a839ff270e/ao2c01567_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0587/9134407/3d1afed1a949/ao2c01567_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0587/9134407/9430465b613a/ao2c01567_0003.jpg

相似文献

1
Discovery of 9,11-Seco-Cholesterol Derivatives as Novel FXR Antagonists.9,11-断-胆固醇衍生物作为新型法尼醇X受体拮抗剂的发现
ACS Omega. 2022 May 12;7(20):17401-17405. doi: 10.1021/acsomega.2c01567. eCollection 2022 May 24.
2
Discovery of novel and selective farnesoid X receptor antagonists through structure-based virtual screening, preliminary structure-activity relationship study, and biological evaluation.通过基于结构的虚拟筛选、初步的结构-活性关系研究和生物学评估发现新型和选择性法尼醇 X 受体拮抗剂。
Eur J Med Chem. 2024 Apr 5;269:116323. doi: 10.1016/j.ejmech.2024.116323. Epub 2024 Mar 18.
3
Investigation around the Oxadiazole Core in the Discovery of a New Chemotype of Potent and Selective FXR Antagonists.新型强效选择性法尼醇X受体拮抗剂化学类型发现中恶二唑核心的研究
ACS Med Chem Lett. 2019 Jan 10;10(4):504-510. doi: 10.1021/acsmedchemlett.8b00534. eCollection 2019 Apr 11.
4
Design, Synthesis, and Biological Evaluation of Novel Nonsteroidal Farnesoid X Receptor (FXR) Antagonists: Molecular Basis of FXR Antagonism.新型非甾体类法尼醇X受体(FXR)拮抗剂的设计、合成及生物学评价:FXR拮抗作用的分子基础
ChemMedChem. 2015 Jul;10(7):1184-99. doi: 10.1002/cmdc.201500136. Epub 2015 May 15.
5
BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination.BRD4抑制和FXR激活在胆汁淤积中各自有益,但联合使用时具有拮抗作用。
JCI Insight. 2020 Dec 8;6(1):141640. doi: 10.1172/jci.insight.141640.
6
Discovery of Natural Products as Novel and Potent FXR Antagonists by Virtual Screening.通过虚拟筛选发现天然产物作为新型强效法尼醇X受体拮抗剂
Front Chem. 2018 Apr 30;6:140. doi: 10.3389/fchem.2018.00140. eCollection 2018.
7
Identification of trisubstituted-pyrazol carboxamide analogs as novel and potent antagonists of farnesoid X receptor.三取代吡唑甲酰胺类似物作为法尼醇X受体新型强效拮抗剂的鉴定
Bioorg Med Chem. 2014 Jun 1;22(11):2919-38. doi: 10.1016/j.bmc.2014.04.014. Epub 2014 Apr 16.
8
Discovery and optimization of 1,3,4-trisubstituted-pyrazolone derivatives as novel, potent, and nonsteroidal farnesoid X receptor (FXR) selective antagonists.发现并优化 1,3,4-三取代吡唑啉酮衍生物作为新型强效非甾体法尼醇 X 受体 (FXR) 选择性拮抗剂。
J Med Chem. 2012 Aug 23;55(16):7037-53. doi: 10.1021/jm3002718. Epub 2012 Aug 10.
9
Investigation on bile acid receptor regulators. Discovery of cholanoic acid derivatives with dual G-protein coupled bile acid receptor 1 (GPBAR1) antagonistic and farnesoid X receptor (FXR) modulatory activity.胆汁酸受体调节剂的研究。具有双G蛋白偶联胆汁酸受体1(GPBAR1)拮抗和法尼醇X受体(FXR)调节活性的胆烷酸衍生物的发现。
Steroids. 2016 Jan;105:59-67. doi: 10.1016/j.steroids.2015.11.003. Epub 2015 Dec 1.
10
Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity.法尼醇X受体、孕烷X受体及组成型雄烷受体在抵御胆汁酸毒性中的互补作用
J Biol Chem. 2003 Nov 14;278(46):45062-71. doi: 10.1074/jbc.M307145200. Epub 2003 Aug 15.

引用本文的文献

1
Insights into the gut-liver axis: mechanisms and emerging therapies in hepatocellular carcinoma.洞悉肠-肝轴:肝细胞癌的机制与新兴疗法
Front Pharmacol. 2025 May 19;16:1595853. doi: 10.3389/fphar.2025.1595853. eCollection 2025.
2
Integrating deep learning and molecular dynamics simulations for FXR antagonist discovery.整合深度学习与分子动力学模拟以发现法尼醇X受体拮抗剂
Mol Divers. 2025 Apr 2. doi: 10.1007/s11030-025-11145-2.
3
Tailoring obeticholic acid activity by iridium(III) complex conjugation to develop a farnesoid X receptor probe.

本文引用的文献

1
Identification of Betulinic Acid Derivatives as Potent TGR5 Agonists with Antidiabetic Effects via Humanized TGR5 Mutant Mice.鉴定桦木酸衍生物为通过人源化 TGR5 突变小鼠具有抗糖尿病作用的强效 TGR5 激动剂。
J Med Chem. 2021 Aug 26;64(16):12181-12199. doi: 10.1021/acs.jmedchem.1c00851. Epub 2021 Aug 18.
2
Discovery of Orally Active and Nonsteroidal Farnesoid X Receptor (FXR) Antagonist with Propensity for Accumulation and Responsiveness in Ileum.具有在回肠中蓄积倾向和反应性的口服活性非甾体类法尼醇X受体(FXR)拮抗剂的发现。
ACS Med Chem Lett. 2021 Feb 24;12(3):420-425. doi: 10.1021/acsmedchemlett.0c00640. eCollection 2021 Mar 11.
3
通过铱(III)配合物共轭来调整奥贝胆酸活性以开发法尼醇X受体探针。
J Adv Res. 2025 May;71:307-316. doi: 10.1016/j.jare.2024.10.028. Epub 2024 Oct 28.
4
Non-12α-Hydroxylated Bile Acids Improve Piglet Growth Performance by Improving Intestinal Flora, Promoting Intestinal Development and Bile Acid Synthesis.非12α-羟基化胆汁酸通过改善肠道菌群、促进肠道发育和胆汁酸合成来提高仔猪生长性能。
Animals (Basel). 2023 Oct 31;13(21):3380. doi: 10.3390/ani13213380.
5
Farnesoid X receptor: From Structure to Function and Its Pharmacology in Liver Fibrosis.法尼醇 X 受体:从结构到功能及其在肝纤维化中的药理学。
Aging Dis. 2024 Aug 1;15(4):1508-1536. doi: 10.14336/AD.2023.0830.
Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism.
鹅去氧胆酸通过独特的 TGR5 和 FXR 信号通路改善葡萄糖稳态。
Cell Metab. 2021 Apr 6;33(4):791-803.e7. doi: 10.1016/j.cmet.2020.11.017. Epub 2020 Dec 17.
4
Mediterranean products as promising source of multi-target agents in the treatment of metabolic syndrome.地中海产品作为治疗代谢综合征多靶点药物的有前途的来源。
Eur J Med Chem. 2020 Jan 15;186:111903. doi: 10.1016/j.ejmech.2019.111903. Epub 2019 Nov 21.
5
Theabrownin from Pu-erh tea attenuates hypercholesterolemia via modulation of gut microbiota and bile acid metabolism.普洱茶中的表没食子儿茶素没食子酸酯通过调节肠道微生物群和胆汁酸代谢来减轻高脂血症。
Nat Commun. 2019 Oct 31;10(1):4971. doi: 10.1038/s41467-019-12896-x.
6
A computer-assisted discovery of novel potential anti-obesity compounds as selective carbonic anhydrase VA inhibitors.计算机辅助发现新型潜在的抗肥胖化合物作为选择性碳酸酐酶 VA 抑制剂。
Eur J Med Chem. 2019 Nov 1;181:111565. doi: 10.1016/j.ejmech.2019.111565. Epub 2019 Jul 27.
7
Investigation around the Oxadiazole Core in the Discovery of a New Chemotype of Potent and Selective FXR Antagonists.新型强效选择性法尼醇X受体拮抗剂化学类型发现中恶二唑核心的研究
ACS Med Chem Lett. 2019 Jan 10;10(4):504-510. doi: 10.1021/acsmedchemlett.8b00534. eCollection 2019 Apr 11.
8
Gut microbiota and intestinal FXR mediate the clinical benefits of metformin.肠道微生物群和肠道 FXR 介导二甲双胍的临床获益。
Nat Med. 2018 Dec;24(12):1919-1929. doi: 10.1038/s41591-018-0222-4. Epub 2018 Nov 5.
9
Structural optimization and in vitro profiling of N-phenylbenzamide-based farnesoid X receptor antagonists.基于 N- 苯基苯甲酰胺的法尼醇 X 受体拮抗剂的结构优化和体外分析。
Bioorg Med Chem. 2018 Aug 7;26(14):4240-4253. doi: 10.1016/j.bmc.2018.07.017. Epub 2018 Jul 11.
10
Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction.肠道选择性法尼酯X受体抑制可改善肥胖相关的代谢功能障碍。
Nat Commun. 2015 Dec 15;6:10166. doi: 10.1038/ncomms10166.